New arthritis drug candidate SHR-3045 tested in healthy volunteers

NCT ID NCT07200596

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study tested a single injection of SHR-3045 in 16 healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. Because this is a very early trial, it does not yet test whether the drug actually helps arthritis patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR-3045

What this could lead to

If this early study shows SHR-3045 is safe, it could lead to larger trials testing whether it can help control rheumatoid arthritis.

What could go wrong

This is a very early Phase 1 trial with only 16 healthy people, not patients. It only checks safety and how the drug moves through the body, not whether it works for arthritis. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Frist Affiliated Hospital of USTC (Anhui Provincial Hospital)

    Hefei, Anhui, 230001, China